$APLT
Applied Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000155837022013398 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.240M $6.125M $8.071M
YoY Change -42.4% -44.69% -17.22%
% of Gross Profit
Research & Development $13.12M $15.40M $15.03M
YoY Change -25.46% 4.01% 4.03%
% of Gross Profit
Depreciation & Amortization $0.00 $1.000K
YoY Change -100.0%
% of Gross Profit
Operating Expenses $19.36M $21.52M $23.10M
YoY Change -31.92% -16.83% -4.54%
Operating Profit -$19.36M -$21.52M -$23.10M
YoY Change -31.92% -16.83% -4.54%
Interest Expense $227.0K $111.0K $76.00K
YoY Change 198.68% -34.32% 0.0%
% of Operating Profit
Other Income/Expense, Net $255.0K -$4.336M -$20.00K
YoY Change 2025.0% -9325.53% -200.0%
Pretax Income -$19.10M -$25.86M -$23.12M
YoY Change -32.79% 0.11% -4.38%
Income Tax
% Of Pretax Income
Net Earnings -$19.10M -$25.86M -$23.12M
YoY Change -32.79% 0.11% -4.38%
Net Earnings / Revenue
Basic Earnings Per Share -$0.40 -$0.96 -$0.88
Diluted Earnings Per Share -$0.40 -$0.96 -$0.88
COMMON SHARES
Basic Shares Outstanding 48.01M 26.90M 26.22M
Diluted Shares Outstanding 48.00M 26.90M 26.22M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.38M $67.72M $55.65M
YoY Change -56.45% -46.09% -62.42%
Cash & Equivalents $40.39M $55.73M $38.21M
Short-Term Investments $6.990M $11.99M $17.44M
Other Short-Term Assets $604.0K $602.0K $455.0K
YoY Change 27.7% 20.4% -92.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $55.51M $76.90M $63.56M
YoY Change -52.53% -43.14% -58.83%
LONG-TERM ASSETS
Property, Plant & Equipment $970.0K $1.081M $1.190M
YoY Change -30.91% -28.32% -25.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $199.0K $199.0K $199.0K
YoY Change -0.5% -1.0% -0.5%
Total Long-Term Assets $1.169M $1.280M $1.389M
YoY Change -27.12% -25.1% -22.83%
TOTAL ASSETS
Total Short-Term Assets $55.51M $76.90M $63.56M
Total Long-Term Assets $1.169M $1.280M $1.389M
Total Assets $56.68M $78.18M $64.95M
YoY Change -52.19% -42.92% -58.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.973M $8.691M $5.922M
YoY Change -23.96% 162.57% 69.2%
Accrued Expenses $14.34M $17.50M $15.59M
YoY Change -31.75% -10.34% -1.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.51M $51.72M $22.22M
YoY Change 50.81% 120.96% 12.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $536.0K $655.0K $773.0K
YoY Change -46.56% -41.2% -35.58%
Total Long-Term Liabilities $536.0K $655.0K $773.0K
YoY Change -46.56% -41.2% -35.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.51M $51.72M $22.22M
Total Long-Term Liabilities $536.0K $655.0K $773.0K
Total Liabilities $47.05M $52.37M $22.99M
YoY Change 47.74% 113.59% 9.48%
SHAREHOLDERS EQUITY
Retained Earnings -$334.4M -$315.3M -$289.4M
YoY Change 39.83% 49.62%
Common Stock $5.000K $5.000K $3.000K
YoY Change 66.67% 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.629M $25.81M $41.96M
YoY Change
Total Liabilities & Shareholders Equity $56.68M $78.18M $64.95M
YoY Change -52.19% -42.92% -58.42%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$19.10M -$25.86M -$23.12M
YoY Change -32.79% 0.11% -4.38%
Depreciation, Depletion And Amortization $0.00 $1.000K
YoY Change -100.0%
Cash From Operating Activities -$19.39M -$18.40M -$24.41M
YoY Change 23.78% -28.99% 9.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.021M $5.529M $9.525M
YoY Change -41.05% -67.05% -138.61%
Cash From Investing Activities $5.021M $5.529M $9.525M
YoY Change -41.05% -67.05% -138.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -971.0K 30.39M -789.0K
YoY Change -10.09% 770.38% -101.07%
NET CHANGE
Cash From Operating Activities -19.39M -18.40M -24.41M
Cash From Investing Activities 5.021M 5.529M 9.525M
Cash From Financing Activities -971.0K 30.39M -789.0K
Net Change In Cash -15.34M 17.51M -15.67M
YoY Change 86.46% -410.42% -158.92%
FREE CASH FLOW
Cash From Operating Activities -$19.39M -$18.40M -$24.41M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46253524
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26215514
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26560185
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25114508
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26901069
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26082525
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26901069
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26082525
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26560185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25114508
dei Entity Central Index Key
EntityCentralIndexKey
0001697532
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25857000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25828000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48978000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-50007000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.99
CY2022Q2 aplt Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q2 us-gaap Operating Lease Liability Statement Of Financial Position Extensible List
OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25857000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25828000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48978000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50007000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38898
dei Entity Registrant Name
EntityRegistrantName
Applied Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3405262
dei Entity Address Address Line1
EntityAddressAddressLine1
545 Fifth Avenue
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1400
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
220-9226
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
APLT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48011354
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55728000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53888000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
11994000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
26935000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26215514
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50007000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89892000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15396000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9176000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7571000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
76898000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
88394000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1081000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1298000
CY2022Q2 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
199000
CY2021Q4 aplt Security Deposit And Leasehold Improvements Net
SecurityDepositAndLeaseholdImprovementsNet
200000
CY2022Q2 us-gaap Assets
Assets
78178000
CY2021Q4 us-gaap Assets
Assets
89892000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
462000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
442000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8691000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9461000
CY2022Q2 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
17787000
CY2021Q4 aplt Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16559000
CY2022Q2 aplt Warrant Liability Current
WarrantLiabilityCurrent
24775000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
51715000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26462000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
655000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
891000
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
655000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
891000
CY2022Q2 us-gaap Liabilities
Liabilities
52370000
CY2021Q4 us-gaap Liabilities
Liabilities
27353000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46253524
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341090000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328958000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-107000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315293000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-266315000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25808000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62539000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78178000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14802000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30426000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29250000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6125000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11073000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14196000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20824000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
21521000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
25875000
us-gaap Operating Expenses
OperatingExpenses
44622000
us-gaap Operating Expenses
OperatingExpenses
50074000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-21521000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25875000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44622000
us-gaap Operating Income Loss
OperatingIncomeLoss
-50074000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
111000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
169000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
187000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
245000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-122000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-186000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-178000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4336000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4356000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-25828000
us-gaap Net Income Loss
NetIncomeLoss
-48978000
us-gaap Net Income Loss
NetIncomeLoss
-50007000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25857000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25828000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48978000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.99
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26901069
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26082525
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26560185
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25114508
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-25828000
us-gaap Net Income Loss
NetIncomeLoss
-48978000
us-gaap Net Income Loss
NetIncomeLoss
-50007000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
86000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-31000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
113000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-73000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
86000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-31000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
113000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-73000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25771000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25859000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48865000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50080000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
81939000
CY2021Q1 aplt Stock Issuance Costs
StockIssuanceCosts
203000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74387000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000
CY2021Q1 aplt Stock Options Exercised For Common Stock Not Yet Issued Value
StockOptionsExercisedForCommonStockNotYetIssuedValue
1000
CY2021Q1 aplt Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
69000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2981000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-24179000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
135221000
CY2021Q2 aplt Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Adjustment
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAdjustment
35000
CY2021Q2 aplt Stock Issued During Period Value Stock Options Exercised In Prior Period
StockIssuedDuringPeriodValueStockOptionsExercisedInPriorPeriod
1000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
341000
CY2021Q2 aplt Stock Options Exercised For Common Stock Not Yet Issued Value
StockOptionsExercisedForCommonStockNotYetIssuedValue
1000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2702000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-25828000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-31000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
112440000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62539000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2077000
CY2022Q1 aplt Adjustments To Additional Paid In Capital Options Issued In Lieu Of Bonus
AdjustmentsToAdditionalPaidInCapitalOptionsIssuedInLieuOfBonus
441000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-23121000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
41963000
CY2022Q2 aplt Stock Issuance Costs
StockIssuanceCosts
96000
CY2022Q2 aplt Stock Issued During Period Value Common Stock Pre Funded Warrants And Common Stock Warrants Sold For Cash
StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash
5968000
CY2022Q2 aplt Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
1417000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2231000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-25857000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
86000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25808000
us-gaap Profit Loss
ProfitLoss
-48978000
us-gaap Profit Loss
ProfitLoss
-50007000
us-gaap Share Based Compensation
ShareBasedCompensation
4308000
us-gaap Share Based Compensation
ShareBasedCompensation
5683000
aplt Options Issued In Lieu Of Bonus
OptionsIssuedInLieuOfBonus
441000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
2024000
aplt Amortization Of Insurance Premium
AmortizationOfInsurancePremium
2046000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
217000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
204000
aplt Amortization Of Leasehold Improvements
AmortizationOfLeaseholdImprovements
1000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-216000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-198000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
4357000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
3105000
aplt Increase Decrease In Financed Insurance Premium
IncreaseDecreaseInFinancedInsurancePremium
4434000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
524000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1482000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-770000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2670000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-565000
aplt Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-2603000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42810000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48121000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
14987000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
94546000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
500000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
30041000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
86154000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15054000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7892000
aplt Proceeds From Issuance Of Shares And Pre Funded Warrants
ProceedsFromIssuanceOfSharesAndPreFundedWarrants
27899000
aplt Cash Stock Issuance Costs
CashStockIssuanceCosts
165000
aplt Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
74420000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
3105000
aplt Proceeds From Financed Insurance Premium
ProceedsFromFinancedInsurancePremium
4434000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1408000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
2350000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
408000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
69000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29596000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76981000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1840000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20968000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53888000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57466000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55728000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78434000
aplt Initial Measurement Of Warrant Liability
InitialMeasurementOfWarrantLiability
21835000
aplt Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
1417000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
113000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-73000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
96000
aplt Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
38000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
27042000
CY2021Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
1000
CY2021Q4 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear
108000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
26935000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11988000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11994000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27042000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
us-gaap Profit Loss
ProfitLoss
-49000000.0
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315300000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
67700000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q2 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear
8000
CY2022Q2 aplt Debt Securities Available For Sale Accumulated Gross Unrealized Loss Before Tax Rolling Within One Year
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear
2000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
11994000
CY2022Q2 aplt Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
11988000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
11994000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27042000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
108000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26935000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
aplt Gross Unrealized Losses Percentage Of Corporate Bond Portfolio Amortized Cost Basis
GrossUnrealizedLossesPercentageOfCorporateBondPortfolioAmortizedCostBasis
0.0001
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
11988000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
108000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26935000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2022Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
90000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
200000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
2001000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
2001000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
108000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
17696000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
108000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
17696000
CY2022Q2 us-gaap Prepaid Rent
PrepaidRent
120000
CY2021Q4 us-gaap Prepaid Rent
PrepaidRent
117000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
109000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
105000
CY2022Q2 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
302000
CY2021Q4 aplt Prepaid Commercial And Patient Advocacy
PrepaidCommercialAndPatientAdvocacy
254000
CY2021Q4 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
279000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
749000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
987000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17787000
CY2022Q2 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
5058000
CY2021Q4 aplt Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
4483000
CY2022Q2 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
2697000
CY2021Q4 aplt Insurance Premium Asset Current
InsurancePremiumAssetCurrent
1616000
CY2022Q2 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
253000
CY2021Q4 aplt Research And Development Tax Credit Receivable
ResearchAndDevelopmentTaxCreditReceivable
502000
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
35000
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
23000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
602000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
471000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9176000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7571000
CY2022Q2 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
11579000
CY2021Q4 aplt Accrued Pre Clinical And Clinical Expenses Current
AccruedPreClinicalAndClinicalExpensesCurrent
9912000
CY2022Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2487000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
789000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
681000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
419000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1052000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2779000
CY2022Q2 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
956000
CY2021Q4 aplt Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
1394000
CY2022Q2 aplt Accrued Patent Expenses Current
AccruedPatentExpensesCurrent
283000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16559000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2231000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2702000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4308000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5683000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
767913
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11500000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
21400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.86
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4704888
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.29
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10305000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
767913
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
271095
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
132269
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
32.85
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5069437
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3613024
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1456413
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
13.26
aplt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
P8Y8M12D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
254000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
515000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Operating Lease Cost
OperatingLeaseCost
126000
us-gaap Operating Lease Cost
OperatingLeaseCost
126000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0569
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
426000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1195000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1117000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25857000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25828000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26901069
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26082525
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-48978000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-50007000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26560185
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25114508
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.99

Files In Submission

Name View Source Status
0001558370-22-013398-index-headers.html Edgar Link pending
0001558370-22-013398-index.html Edgar Link pending
0001558370-22-013398.txt Edgar Link pending
0001558370-22-013398-xbrl.zip Edgar Link pending
aplt-20220630.xsd Edgar Link pending
aplt-20220630x10q.htm Edgar Link pending
aplt-20220630xex31d1.htm Edgar Link pending
aplt-20220630xex31d2.htm Edgar Link pending
aplt-20220630xex32d1.htm Edgar Link pending
aplt-20220630xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
aplt-20220630_cal.xml Edgar Link unprocessable
aplt-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
aplt-20220630_def.xml Edgar Link unprocessable
aplt-20220630_lab.xml Edgar Link unprocessable
aplt-20220630x10q_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending